SOURCE: Living Cell Technologies

July 16, 2008 23:54 ET

Living Cell Technologies Hosts Diabetes Seminar for World Leaders in Porcine Islet Implants in Humans

MELBOURNE, AUSTRALIA and AUCKLAND, NEW ZEALAND--(Marketwire - July 16, 2008) - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today announced that Professor Bob Elliott, Medical Director of LCT, will host a seminar on Friday, August 8, 2008, in Auckland, New Zealand for world leading medical scientists and specialists to discuss current developments with porcine islet transplant technologies.

The one day meeting brings together experts with many years experience who are developing methods for delivering insulin producing cells to patients with insulin dependant Type 1 diabetes. The topics they will address include the health status of the pigs whose insulin producing cells are implanted into humans, the absence of immunosuppression drugs, early clinical data from human studies and post transplant monitoring.

World leading experts, Professor David White, Robarts Institute Canada; Professor Gregory Korbutt, University of Alberta, Canada; Professor Nikolai Skaletsky, the Sklifosovsky Institute, Moscow; Professor Riccaardo Calafiore, University of Perugia, Italy and Dr. Linda Scobie, University of Glasgow, will be presenting at the seminar, among others.

Professor Elliott said: "We are delighted to have so many islet implant experts participating in this meeting which will be very focused on the issues surrounding human trials. The early results that have been obtained to date from LCT's porcine islet implants have been extremely encouraging. I look forward to discussing the results with fellow scientists and practitioners who see the importance of islet cell treatment and are keen to advance this technology rapidly for the benefit of people with insulin dependent Type 1 diabetes."

About Living Cell Technologies:

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company implants micro-encapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. The Company is developing treatments for Huntington's disease and other neurological disorders that involve implantation of micro-encapsulated choroid plexus cells to deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology has the potential for allowing healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also is developing medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes. The changes in this paragraph reflect that the company is only developing or may develop certain products, and is not manufacturing or selling any products other than DiabeCell.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of July 17, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.